Cladribine Tablets as an Exit Therapy Strategy

Not yet recruitingOBSERVATIONAL

Enrollment

450

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis

Interventions

DRUG

Cladribine

To evaluate the clinical activity during the 2 years of follow-up in patients switching to cladribine and continuing current DMT

Trial Locations (1)

Service de neurologie - Hôpitaux Universitaires de Strasbourg, Strasbourg

All Listed Sponsors

lead

University Hospital, Strasbourg, France

OTHER

NCT06887426 - Cladribine Tablets as an Exit Therapy Strategy | Biotech Hunter | Biotech Hunter